JSA-201

JSA-201 is a synthetic small molecule therapeutic candidate developed by CellMed for the treatment of solid tumors. It was designed using Computer-Aided Drug Design (CADD) and a synthetic lethality approach, a strategy that targets specific genetic vulnerabilities in cancer cells to induce cell death while minimizing impact on healthy tissue. Although the specific molecular target of JSA-201 has not been publicly disclosed by CellMed, the asset has been granted Orphan Drug Designation (ODD). It is currently positioned within CellMed's synthetic drug pipeline alongside other oncology and anti-inflammatory candidates.